COMPANY PROFILE

Shennon Biotechnologies

Explore full profile

Precision T-cell engager immunotherapies for solid tumours

San Francisco, United StatesFounded 2021Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Shennon Biotechnologies

Shennon Biotechnologies is a San Francisco-based biotech company, founded in 2021, developing precision immunotherapies for solid tumours, focused on T-cell engagers (TCEs). Its discovery platform combines target discovery, ultra-high-throughput microfluidic functional screening, computational design and safety prediction; its TCELERATOR system profiles more than 10 million single-cell interactions at once. The company is advancing three TCE programmes: SBT-121, a trispecific antibody-based TCE for small cell lung cancer; SBT-201, an antibody-based TCE for ovarian cancer; and SBT-425, a TCR-based TCE for hepatocellular carcinoma. On 14 September 2026 Shennon announced a $12 million financing from new investors Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures and Saras Capital, with existing investors DCVC, Foundation Capital and AV8 Ventures, bringing total funding to $25 million. It also appointed Cyril Konto, M.D., formerly Chief Medical Officer of Arcus Biosciences and previously at Genentech/Roche, as CEO, with founder Li Sun, PhD becoming President and CTO, as the company moves from platform building to development-stage execution. Sources: Business Wire (BioSpace) 14 Sep 2026; FinSMEs 14 Sep 2026; BioXconomy 15 Sep 2026.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: San Francisco, United States
Employees: 16
Open positions: 2
Dealroom signal: 75.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Mar 2023	$13M	$52M	DCVC · Foundation Capital · AV8 Ventures	↗
SPINOUT✓Other financing	Jan 2021	—	—	Harvard University	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Shennon Biotechnologies website traffic

Latest recorded traffic for Shennon Biotechnologies is 2.5K monthly website visits, up 108.3% over the last three months. Shennon Biotechnologies's team grew 0% over the past year.

Latest monthly visits2.5K 3-month web change+108.3% 1-year team growth0%

Monthly website visitsMar 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Lab Technician for Microfabrication (part-time) San Francisco, CASan Francisco, California, United States, Northern America, Americas · Other · Aug 28, 2026 Lab Technician (part-time)San Francisco, CA · Other · Aug 26, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational	—	$5.1M	—
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
KBKOTAI BiotechnologiesHigh-throughput structural modeling and analysis for immune cell sequences	Suita-Shi, Japan	Operational
OLOlgramInnovations from the sea to tackle antibiotic resistance \| Olgram	Paris, France	Operational